Article

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

2020-10-27

Abstract excerpt

Allosteric inhibitors of mutant IDH1 or IDH2 induce terminal differentiation of the mutant leukemic blasts and provide durable clinical responses in approximately 40% of acute myeloid leukemia (AML) patients with the mutations. However, primary resistance and acquired resistance to the drugs are major clinical issues. To understand the molecular underpinnings of clinical resistance to IDH inhibitors (IDHi), we per...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e2d6b9da-9cac-58d8-9df3-dcef4eba0efd
DOI: 10.1101/2020.10.27.357111

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemiaDOI 10.1101/2020.10.27.357111Read

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemiaSemantic proximity Read

Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.Semantic proximity Read

Resistance to mutant IDH inhibitors in acute myeloid leukemia: Molecular mechanisms and therapeutic strategies.Semantic proximity Read

Dynamic heterogeneity towards drug resistance in AML cells is primarily driven by epigenomic mechanism unveiled by multi-omics analysisSemantic proximity Read

Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapseSemantic proximity Read

An arms‐race against resistance: leukemic stem cells and lineage plasticitySemantic proximity Read

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.Semantic proximity Read

A Single-cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid LeukemiaSemantic proximity Read

Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness.Semantic proximity Read

Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.Semantic proximity Read

The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid LeukemiaSemantic proximity Read

DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.Semantic proximity Read